Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients

BACKGROUND: Coronavirus disease 2019 (COVID-19) raises particular concerns for people with multiple sclerosis (PwMS) on disease-modifying treatments (DMTs), and for physicians caring for them. The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on PwMS receiving DMTs...

Descripción completa

Detalles Bibliográficos
Autores principales: Mallucci, Giulia, Zito, Antonio, Baldanti, Fausto, Gastaldi, Matteo, Fabbro, Beatrice Dal, Franciotta, Diego, Bergamaschi, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836789/
https://www.ncbi.nlm.nih.gov/pubmed/33609958
http://dx.doi.org/10.1016/j.msard.2021.102754

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836789/
https://www.ncbi.nlm.nih.gov/pubmed/33609958
http://dx.doi.org/10.1016/j.msard.2021.102754

Ejemplares similares